Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):257-287. doi: 10.3760/cma.j.cn112152-20200120-00049.
The formulation of the guidelines for the clinical diagnosis and treatment of lung cancer in line with China's national conditions and multiple discipline cooperation plays an important role in standardizing prevention measures and improving the diagnosis and treatment of lung cancer in China. In order to further improve the diagnosis and treatment of lung cancer in China, improve the outcomes of patients, and provide professional evidence-based medicine advice to clinicians at all levels, the Chinese Medical Association organized specialists in departments of pulmonary medicine, oncology medicine, thoracic surgery, radiotherapy, radiology and pathology throughout the country to perform the work. The recent advances in pathology, genetic testing, immuno-molecule testing, and therapeutic approaches were integrated and the guideline was formulated in combination with international guidelines and China's national conditions. The guideline aims to provide evidence-based, guidance for clinicians at all levels. The guideline covers the screening, diagnosis, pathology, treatment and follow-up of lung cancer.
制定符合中国国情的肺癌临床诊疗指南并开展多学科合作,对规范我国肺癌防治措施、提高肺癌诊疗水平具有重要作用。为进一步提高我国肺癌诊疗水平,改善患者预后,为各级临床医师提供专业的循证医学建议,中华医学会组织全国呼吸内科、肿瘤内科、胸外科、放疗科、放射科及病理科等领域的专家开展此项工作。整合病理学、基因检测、免疫分子检测及治疗方法等方面的最新进展,并结合国际指南和中国国情制定本指南。本指南旨在为各级临床医师提供循证指导。指南涵盖肺癌的筛查、诊断、病理、治疗及随访等内容。